Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibody-based cancer therapeutics - Affimed Therapeutics

Drug Profile

Research programme: antibody-based cancer therapeutics - Affimed Therapeutics

Alternative Names: AFM 12; AFM 18; AFM 20; AFM 21; AFM 22; AFM 24; AFM 24+; AFM 26; AFM 26+; AFM24_I; AFM24_T; anti CD19 x anti CD16; anti CD33 X anti CD3; anti-EGFRvIII/CD16A Tand AB; anti-EGFRvIII/CD3 TandAb; anti-EpCAM TandAb; Antibody-based non-Hodgkin's lymphoma therapeutics - Affimed; MHC-peptide complex antibody - Affimed; Trispecific Abs

Latest Information Update: 16 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Affimed Therapeutics
  • Developer Affimed Therapeutics; Amphivena Therapeutics
  • Class Bispecific antibodies; Monoclonal antibodies; Trispecific antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; B-cell maturation antigen modulators; CD19 antigen modulators; CD200 antigen modulators; CD3 antigen modulators; CD33 antigen modulators; Epidermal growth factor receptor antagonists; Epithelial cell adhesion molecule inhibitors; Fc gamma receptor IIIA modulators; Immunomodulators; Major histocompatibility complex inhibitors; Matrix metalloproteinase 1 inhibitors; Natural killer cell stimulants; T lymphocyte stimulants; T-lymphocyte differentiation antigen agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Cancer; Colorectal cancer; Head and neck cancer; Lung cancer; Multiple myeloma
  • No development reported Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 08 Aug 2018 Affimed enters into a preclinical research collaboration with Nektar Therapeutics
  • 08 Aug 2018 Affimed anticipates to complete IND-enabling studies by mid-2019
  • 28 May 2018 No recent reports of development identified for preclinical development in Solid-tumours in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top